Oldest pages

Showing below up to 50 results in range #51 to #100.

51. Property:Were side effects systematically recorded (12:00, 4 April 2024)
52. Property:Effect sizes reported (12:00, 4 April 2024)
53. Property:Mono- or multicentric (12:01, 4 April 2024)
54. Property:Side effects taken into account in the interpretation of the results (11:31, 5 April 2024)
55. Property:Overall confidence in the results of the review (07:47, 10 April 2024)
56. Property:Blinding (09:42, 10 April 2024)
57. Property:Side Effects / Interactions (11:53, 16 April 2024)
58. Property:Drop-out reasons (12:04, 16 April 2024)
59. Property:Overall Drop-out (12:21, 16 April 2024)
60. Property:Author's Quality Assessment of Included Studies (12:55, 16 April 2024)
61. Property:Number of studies (arm) (06:48, 25 April 2024)
62. Property:Authors Abstract (07:32, 25 April 2024)
63. Property:Specifications on cancer therapies (08:12, 25 April 2024)
64. Property:Further points on quality assessment (08:21, 25 April 2024)
65. Property:Gender specifications (08:26, 25 April 2024)
66. Property:LoE (08:40, 25 April 2024)
67. Property:N randomized (08:53, 25 April 2024)
68. Property:Other sources of bias (08:55, 25 April 2024)
69. Property:Bias due to deviation from intended intervention (adhering to intervention) (09:13, 25 April 2024)
70. Property:Bias due to deviation from intended intervention (assignment to intervention) (09:13, 25 April 2024)
71. Property:Results during intervention (09:32, 25 April 2024)
72. Property:Results after intervention (09:32, 25 April 2024)
73. Jeon, Y (13:58, 8 May 2024)
74. Property:One-time application (07:54, 17 May 2024)
75. Property:Duration in days (08:07, 17 May 2024)
76. Property:Specifications on analyses (08:14, 17 May 2024)
77. Arbabi-kalati, F (11:20, 30 May 2024)
78. Deghatipour, M (11:21, 30 May 2024)
79. Palmeira, P (13:41, 30 May 2024)
80. Property:Order number (12:53, 6 June 2024)
81. Property:Analysis (11:38, 9 June 2024)
82. Publication: Effect of intravenous high dose Vitamin C on postoperative pain and morphine use after laparoscopic colectomy: A randomized controlled trial (12:38, 10 June 2024)
83. Publication: Efficacy of Vitamin A in the Prevention of Locoregional Recurrence and Second Primaries in Head and Neck Cancer (06:31, 13 June 2024)
84. Publication: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Retinol Palmitate (Vitamin A) for Symptomatic Chronic Radiation Proctopathy (07:05, 13 June 2024)
85. Publication: Phase I randomised double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases - safety, pharmacokinetics and pharmacodynamics (08:27, 13 June 2024)
86. Publication: Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4) (13:56, 13 June 2024)
87. Publication: Evaluation of the efficacy of zinc sulfate in the prevention of chemotherapy-induced mucositis: A double-blind randomized clinical trial (14:01, 13 June 2024)
88. Publication: Effect of Zinc Supplementation on Serological Response to Vaccination Against Streptococcus Pneumoniae in Patients Undergoing Chemotherapy for Colorectal Cancer (14:05, 13 June 2024)
89. Publication: Zinc sulfate in the prevention of radiation-induced oropharyngeal mucositis: a prospective, placebo-controlled, randomized study (14:06, 13 June 2024)
90. Publication: The effect of zinc sulphate in the prevention of radiation induced oral mucositis in patents with head and neck cancer (14:09, 13 June 2024)
91. Publication: High-dose zinc oral supplementation after stem cell transplantation causes an increase of TRECs and CD4+ naive lymphocytes and prevents TTV reactivation (18:11, 13 June 2024)
92. Publication: Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study (19:18, 13 June 2024)
93. Publication: Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer Trial (06:30, 14 June 2024)
94. Property:Drop-out (15:13, 19 June 2024)
95. Howells, LM (07:32, 20 June 2024)
96. Berry, DP (07:33, 20 June 2024)
97. Elliott, PJ (07:33, 20 June 2024)
98. Jacobson, EW (07:33, 20 June 2024)
99. Hoffmann, E (07:34, 20 June 2024)
100. Hegarty, B (07:34, 20 June 2024)